Offline dengan aplikasi Player FM !
WashU Researcher to study "Natural Killer" cells as treatment for recurrent childhood brain tumors
Manage episode 438207569 series 1511392
St. Louis researchers are participating in a larger study of children and young adults with recurrent brain tumors. The trial will test a promising type of immunotherapy using Natural Killer -- or N-K cells -- a type of immune cell that can recognize and kill cancer cells while sparing healthy cells.
The research is being supported by a two-million-dollar grant from CureSearch for Children’s Cancer
KMOX's Megan Lynch gets mre from Dr. Mohamed Abdelbaki Associate Professor of Pediatrics at Washington University School of Medicine in St. Louis, Missouri. He also serves as the Director of both the Pediatric Neuro Oncology Program and the Clinical Research Office (CRO) for the Pediatric Hematology, Oncology and Bone Marrow Transplant Division at St. Louis Children's Hospital.
505 episode
Manage episode 438207569 series 1511392
St. Louis researchers are participating in a larger study of children and young adults with recurrent brain tumors. The trial will test a promising type of immunotherapy using Natural Killer -- or N-K cells -- a type of immune cell that can recognize and kill cancer cells while sparing healthy cells.
The research is being supported by a two-million-dollar grant from CureSearch for Children’s Cancer
KMOX's Megan Lynch gets mre from Dr. Mohamed Abdelbaki Associate Professor of Pediatrics at Washington University School of Medicine in St. Louis, Missouri. He also serves as the Director of both the Pediatric Neuro Oncology Program and the Clinical Research Office (CRO) for the Pediatric Hematology, Oncology and Bone Marrow Transplant Division at St. Louis Children's Hospital.
505 episode
All episodes
×Selamat datang di Player FM!
Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.